National Bank of Canada
PLX icon

National Bank of Canada’s Protalix BioTherapeutics PLX Stock Holding History

National Bank of Canada’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-279
Closed -$43.5K – 2855
2023
Q3 		$43.5K Sell
279
-2,698
-91% -$4.84K ﹤0.01% 1843
2023
Q2 		$548K Buy
+2,977
New +$7.09K ﹤0.01% 1273

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

National Bank of Canada's PLX Position: Q1 2026 in Review

National Bank of Canada opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 2,000 shares worth $4.36K. The stake represents ﹤0.01% of the portfolio and ranks #2489 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in PLX as recently as Q3 2024.

National Bank of Canada first reported a position in PLX in Q4 2021 and has held it in 13 quarters since. The position peaked at $560K in Q2 2023. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • National Bank of Canada held 2,000 shares of Protalix BioTherapeutics worth $4.36K as of Q1 2026.
  • Protalix BioTherapeutics was a new National Bank of Canada position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2489 holding.
  • National Bank of Canada first reported a position in Protalix BioTherapeutics in Q4 2021 and has held it in 13 quarters since.
  • National Bank of Canada's Protalix BioTherapeutics position peaked at $560K in Q2 2023.
  • 100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.